Evidence map›Paper›PMID 41129082›Full record

ArticleInternational ophthalmology2025

The clinical profile and therapeutic outcome of patients diagnosed with "atypical" optic neuritis.

Gülden Akdal, Hülya Ertaşoğlu Toydemir, Meltem Söylev Bajin, Pınar Özçelik, Figen Gökçay, Ayşe İlksen Işıkay, Canan Togay Işıkay, Şebnem Bıçakçı, Aylin Yaman, Pembe Keskinoğlu and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Gülden AkdalFaculty of Medicine, Department of Neurology, Dokuz Eylül University, Izmir, Turkey. gulden.akdal@deu.edu.tr.ORCID http://orcid.org/0000-0002-2486-4490
Hülya Ertaşoğlu ToydemirDepartment of Neurology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Health Sciences University, Istanbul, Turkey.
Meltem Söylev BajinFaculty of Medicine, Department of Ophthalmology, Dokuz Eylül University, Izmir, Turkey.
Pınar ÖzçelikFaculty of Medicine, Department of Neurology, Dokuz Eylül University, Izmir, Turkey.
Figen GökçayFaculty of Medicine, Department of Neurology, Ege University, Izmir, Turkey.
Ayşe İlksen IşıkayFaculty of Medicine, Department of Neurology, Hacettepe University, Ankara, Turkey.
Canan Togay IşıkayFaculty of Medicine, Department of Neurology, Ankara University, Ankara, Turkey.
Şebnem BıçakçıFaculty of Medicine, Department of Neurology, Cukurova University, Adana, Turkey.
Aylin YamanFaculty of Medicine, Department of Ophthalmology, Dokuz Eylül University, Izmir, Turkey.
Pembe KeskinoğluFaculty of Medicine, Department of Biostatistics, Dokuz Eylül University, Izmir, Turkey.
Neşe ÇelebisoyFaculty of Medicine, Department of Neurology, Ege University, Izmir, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOur aim was to evaluate the clinical characteristics and prognosis of patients diagnosed with atypical optic neuritis (AON).

methodsWe performed a retrospective study in patients with AON collected between 1991 and 2024. Clinical features, laboratory findings, and treatment modalities of patients with AON were investigated and the relationship between therapeutic approaches and the visual prognosis of these patients were evaluated.

resultsEighty-eight patients with AON were evaluated and 51 patients were included in the study. Patients were divided in two groups (Group 1: full recovery, Group 2: partial and no recovery). Anti-MOG antibodies were positive in 8 patients. Seven patients out of 8 had full recovery whereas 1 patient had partial recovery. Among 7 patients with AQP4-Ab positivity, 4 patients had no recovery, 1 patient had partial recovery and 2 patients had full recovery. MOG-Ab positivity and intravenous methylprednisolone (IVMP) treatment in patients with full recovery were found to be significantly higher than in patients with partial recovery and no recovery (p = 0.011 and p = 0.010 respectively). Patients who were treated with plasma exchange (PE), intravenous immunoglobulin (IVIg) and immunsupressive agents had longer recovery time according to Kaplan -Meier survival curves (p = 0.023, p = 0.039 and p = 0.032).

conclusionMOG-Ab positivity and IVMP treatment are related with better visual outcome. Early diagnosis and treatment of AON are extremely important to rescue vision. Treatment in patients with AON should be started as soon as possible, even if the serological status is not known at the setting of ON.

Indexed as

Immunoglobulins, IntravenousMethylprednisoloneOptic NeuritisPlasma ExchangeVisual AcuityAdolescentAdultAgedAutoantibodiesFemaleFollow-Up StudiesGlucocorticoidsHumansMaleMiddle AgedPrognosisAutoantibodiesGlucocorticoidsImmunoglobulins, IntravenousMethylprednisoloneAquaporin-4 antibodyAtypical optic neuritisMyelin oligodendrocyte glycoprotein antibodyOptic neuritis

Identifiers

PMID41129082

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.